Core Viewpoint - The company confirmed that the funds and interest occupied by the actual controller have been fully returned, and it is actively developing innovative traditional Chinese medicine projects [2]. Group 1: Financial Integrity - The actual controller of the company has returned all occupied funds and interest [2]. - There is no indication of these transactions on the balance sheet, raising questions from investors [2]. Group 2: Product Development - The company is focusing on innovative traditional Chinese medicine products, including projects like Shen Dan Tong Nao Drop, Huang Jia Ruan Gan Granule, and new drugs such as Kai Xin San and Jin Shui Liu Jun Decoction [2]. - The company has provided detailed progress updates in its regular reports and will disclose any relevant matters as required [2].